- Trials with a EudraCT protocol (72)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
72 result(s) found for: Population standard deviation.
Displaying page 1 of 4.
EudraCT Number: 2004-002991-40 | Sponsor Protocol Number: A6281269 | Start Date*: 2015-04-01 |
Sponsor Name:Pfizer Inc | ||
Full Title: Evolution of Growth Rate in Children Suffering From a Disease Associated With Growth Retardation and Treated by Genotonorm. A Pilot Study | ||
Medical condition: Growth Disorders, Growth Retardation | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2015-001708-69 | Sponsor Protocol Number: 20184 | Start Date*: 2015-07-15 |
Sponsor Name:Merck KGaA | ||
Full Title: An Open Study of the Safety and Efficacy of Saizen®, (Recombinant Human Growth Hormone, r-hGH), in Children Born With Serious Intra-uterine Growth Retardation (IUGR) Treated to Final Height | ||
Medical condition: Children Born With Serious Intra-uterine Growth Retardation | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2020-000280-23 | Sponsor Protocol Number: BISS | Start Date*: 2020-08-20 | ||||||||||||||||
Sponsor Name:Prof Mathias Abegg | ||||||||||||||||||
Full Title: A pragmatic, randomized, non-inferiority trial comparing the effectiveness of Botulinum toxin-based treatment with conventional strabismus surgery in acquired esotropia | ||||||||||||||||||
Medical condition: Acquired esotropia (strabismus) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001696-51 | Sponsor Protocol Number: 25735 | Start Date*: 2015-07-15 |
Sponsor Name:Merck KGaA [...] | ||
Full Title: Optimization of the Dosage Regimen With Growth Hormone Therapy in Children Born Small for Gestational Age. An Open Label, Randomized, Pilot Study, Comparing in Children Treated for 3 Years, the Eff... | ||
Medical condition: Small for Gestational Age (SGA) | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2020-002974-28 | Sponsor Protocol Number: NN8640-4468 | Start Date*: 2023-07-12 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: A trial comparing the efficacy and safety of once weekly dosing of somapacitan with daily Norditropin® in Chinese children with growth hormone deficiency | |||||||||||||
Medical condition: Growth hormone deficiency in children | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-003451-34 | Sponsor Protocol Number: intrusion | Start Date*: 2023-05-03 |
Sponsor Name:Erasmus Medical Center | ||
Full Title: INTRUSION: Unraveling the INTRatUmoral PK/PD relatION for SAR408701 | ||
Medical condition: metastatic non-squamous non-small cell lung cancer metastatic estrogen positive breast cancer metastatic gastric cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2005-000574-40 | Sponsor Protocol Number: PSP-CoQ10 | Start Date*: 2006-04-24 |
Sponsor Name:Kompetenznetz Parkinson e.V. | ||
Full Title: Brain Energy Metabolism in Progressive Supranuclear Palsy: Comparison of PSP Patients and Healthy Controls and Effect of Coenzyme Q10 – nanoQuinon® | ||
Medical condition: PSP is a sporadic neurodegenerative disorder resulting in a Parkinson syndrome with postural instability, oculomotor deficits, and cognitive decline. With an average annual incidence of 5.3 / 10... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-003016-45 | Sponsor Protocol Number: APCP-112 | Start Date*: 2013-09-11 |
Sponsor Name:Araim Pharmaceuticals | ||
Full Title: A double blind, placebo controlled Phase 2 dose ranging study of the effects of ARA 290 on corneal nerve fiber density and neuropathic symptoms of patients with sarcoidosis | ||
Medical condition: small fiber neuropathy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-000356-17 | Sponsor Protocol Number: 2 79 58035 700 | Start Date*: Information not available in EudraCT |
Sponsor Name:Beaufour Ipsen Pharma | ||
Full Title: PHASE IIIB, INTERNATIONAL, SINGLE GROUP, OPEN STUDY TO DEFINE AN OPTIMAL MONITORING OF IGF-I IN CHILDREN TREATED WITH NUTROPINAQ USING A NOVEL CAPILLARY BLOOD COLLECTION METHOD | ||
Medical condition: growth failure associated with: - inadequate growth hormone secretion - Turner syndrome, confirmed by karyotype - chronic renal insufficiency up to renal transplantation | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: ES (Ongoing) IT (Completed) DK (Completed) AT (Completed) SE (Completed) FI (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-003079-31 | Sponsor Protocol Number: QRK207 | Start Date*: 2016-10-20 | |||||||||||
Sponsor Name:Quark Pharmaceuticals Inc. | |||||||||||||
Full Title: A PHASE 2/3, RANDOMIZED, DOUBLE-MASKED, SHAMCONTROLLED TRIAL OF QPI-1007 DELIVERED BY SINGLE OR MULTI-DOSE INTRAVITREAL INJECTION(S) TO SUBJECTS WITH ACUTE NONARTERITIC ANTERIOR ISCHEMIC OPTIC NEU... | |||||||||||||
Medical condition: NAION typically presents as an abrupt, painless monocular vision loss. Visual loss varies widely, ranging from visual field loss only to complete blindness. The neuronal degeneration process in N... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000446-56 | Sponsor Protocol Number: CRT076 | Start Date*: 2016-03-07 | |||||||||||
Sponsor Name:Cristália Produtos Químicos Farmacêuticos Ltda. | |||||||||||||
Full Title: Clinical study to compare recombinant human growth hormone Cristalia (r-hGH Cristalia) versus Genotropin® in prepubertal children with growth deficiency due to deficiency of growth hormone. | |||||||||||||
Medical condition: Growth deficiency due to growth hormone deficiency | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003365-99 | Sponsor Protocol Number: NL62809.068.17 | Start Date*: 2017-11-08 |
Sponsor Name:Maastricht University | ||
Full Title: The effects of ceasing opioid, benzodiazepine, or Z-hypnotic drug use on measures of driving performance and postural balance. | ||
Medical condition: Insomnia, Anxiety, chronic pain | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2020-004137-21 | Sponsor Protocol Number: 78591.041.21 | Start Date*: 2021-10-28 |
Sponsor Name:University Medical Center Utrecht | ||
Full Title: Effect of intranasal administration of palivizumab on experimental respiratory syncytial viral infection – a human challenge study | ||
Medical condition: respiratory syncytial virus infection | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2019-002691-14 | Sponsor Protocol Number: RC2019.1.6_ROSSI | Start Date*: 2019-10-30 | |||||||||||
Sponsor Name:IRCCS, OSPEDALE PEDIATRICO BAMBINO GESÙ DI ROMA | |||||||||||||
Full Title: VISCOUS BUDESONIDE IN PATIENTS AFFECTED BY EOSINOPHILIC ESOPHAGITIS, OPERATED FOR ESOPHAGEAL ATRESIA | |||||||||||||
Medical condition: Eosinophilicesophagitis (EoE) in Esophageal atresia (EA). | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-016631-35 | Sponsor Protocol Number: NCT-2009-11-02-53 | Start Date*: 2010-09-13 | |||||||||||
Sponsor Name:Universitätsklinikum Heidelberg | |||||||||||||
Full Title: Phase II Trial of Ipilimumab in Patients with advanced melanoma and spontaneous preexisting immune response to NY-ESO-1 | |||||||||||||
Medical condition: patients with advanced melanoma and spontaneous preexisting immune response to NY-ESO-1. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-004713-15 | Sponsor Protocol Number: 1235-SR-1005 | Start Date*: 2006-02-02 |
Sponsor Name:Cardiome Pharma Corp. | ||
Full Title: A Pilot Phase II, Randomised, Double-blind, Placebo-controlled, Multi-centred Safety, Tolerability and Preliminary Efficacy Study of RSD1235-SR for the Prevention of Atrial Fibrillation/Atrial Flut... | ||
Medical condition: Atrial fibrillation is the most common arrhythmia encountered in clinical practice. Atrial fibrillation is usually associated with age and general physical condition, rather than with a specific ca... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) CZ (Completed) DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-004338-42 | Sponsor Protocol Number: CV185-023 | Start Date*: 2006-06-24 |
Sponsor Name:Bristol Myers Squibb International Corporation | ||
Full Title: A Phase 2, Placebo-Controlled, Randomized, Double-Blind, Parallel Arm, Dose Ranging Study to Evaluate Safety and Efficacy of Apixaban In Patients with a Recent Acute Coronary Syndrome. Revised Pr... | ||
Medical condition: ACUTE CORONARY SYNDROMES,NOS | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) NL (Completed) GB (Completed) ES (Completed) BE (Completed) DE (Completed) DK (Completed) AT (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-005033-22 | Sponsor Protocol Number: UOL001362 | Start Date*: 2019-06-19 | |||||||||||
Sponsor Name:University of Liverpool | |||||||||||||
Full Title: In patients taking Protease Inhibitors does switching to a Bictegravir, Tenofovir Alafenamide and Emtricitabine combination, reduce cardiovascular risk: An open-label, randomised, serial CT pilot s... | |||||||||||||
Medical condition: Human immunodeficiency virus (HIV) and cardiovascular disease (CVD) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-001965-33 | Sponsor Protocol Number: AC-052-366 | Start Date*: 2005-11-01 | |||||||||||
Sponsor Name:Actelion Pharmaceuticals Ltd. | |||||||||||||
Full Title: Prospective, randomized, placebo-controlled, double-blind, multicenter, parallel group study to assess the efficacy, safety and tolerability of bosentan in patients with inoperable chronic thromboe... | |||||||||||||
Medical condition: Inoperable chronic thromboembolic pulmonary hypertension (CTEPH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) ES (Completed) AT (Completed) CZ (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-005033-31 | Sponsor Protocol Number: SIK-FR14-1 | Start Date*: 2015-02-06 | |||||||||||
Sponsor Name:Addmedica S.A.S | |||||||||||||
Full Title: Evaluation of the impact of renal function on the pharmacokinetics of hydroxyurea (Siklos®) in patients with sickle cell disease with normal renal function, with hyperfiltration, or with renal fail... | |||||||||||||
Medical condition: Siklos is indicated for the prevention of recurrent painful vaso-occlusive crises including acute chest syndrome in adults, adolescents and children older than 2 years suffering from symptomatic si... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
